Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Funding for life science startups seeking to raise capital has been tight for the past four years. While there was optimism that 2025 may change the tide, we have not yet seen an ease in the flow of ...

Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional ...